Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Antiviral Agents

Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir

Emanuele Focà, Andrea Calcagno, Andrea Bonito, Jessica Cusato, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Filippo Castelnuovo, Giovanni Di Perri, Francesco Castelli, Stefano Bonora
Emanuele Focà
Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emanuele Focà
Andrea Calcagno
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Bonito
Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Cusato
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabetta Domenighini
Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio D'Avolio
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio D'Avolio
Eugenia Quiros Roldan
Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Trentini
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filippo Castelnuovo
Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Di Perri
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Castelli
Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00309-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Atazanavir-ritonavir concentrations change over time during pregnancy in HIV-positive patients; the impact of genetic variants is unknown. Twenty patients were enrolled in this study; plasma and intracellular concentrations of antiretrovirals were measured, in addition to single-nucleotide polymorphisms in transport-related genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1- and pregnane-X-receptor-encoding genes affected third-trimester atazanavir exposure. In this prospective study, genetic variants partially explained the observed interpatient variability in third-trimester exposure to antiretrovirals.

TEXT

Antiretroviral (ARV) treatment of HIV-infected pregnant women is a key element to preventing mother-to-child HIV transmission (MTCT) (1). Despite the target of ARVs being intracellular, knowledge of the pharmacokinetics of these compounds mostly derives from plasma concentration. Some reports suggested a potential correlation between the intracellular (IC) protease inhibitor (PI) concentrations, their activities, and clinical outcomes (2–7). One of the most preferred classes of anchor drugs of ARV regimen during pregnancy are protease inhibitors (PIs); however, several changes in PI exposure have been reported in the third trimester (10). Following oral administration, this class of drugs is primarily metabolized by cytochrome P450 (CYP) 3A4 and is a substrate of the transmembrane efflux pump P-glycoprotein (P-gp) and of the organic anion transporters protein 1B1 (OATP1B1) (8, 9).

All of these steps may be mediated by proteins regulated by different genes. Single-nucleotide polymorphisms (SNPs) in pregnane-X-receptor (PXR), P-gp, and OATP1B1 have been involved in intracellular drug penetration (10, 11). PXR is a nuclear transcription factor that influences the expression of P-glycoprotein (26); PXR regulates the expression of CYP3A4 and ABCB1 and is associated with atazanavir plasma concentration (T allele at position 63396) (12, 13). Several studies have reported a relationship between the ABCB1 3435 C/T polymorphism and PI activity (14, 15). SNPs in the OATP1B1-encoding gene, in particular the 521C allele, have been associated with a decrease in PI transport, both in vitro and in vivo (16–19). Pregnancy induces changes in systemic gene expression, but there are a lack of data about transporting genes changes during pregnancy (20).

The aim of this study was to evaluate changes in atazanavir (ATV) and ritonavir (RTV) plasma/IC concentrations during pregnancy according to SNPs in PXR-, P-gp-, and OATP1B1-encoding genes.

HIV-positive pregnant patients treated with an ATV-RTV combination (300/100 mg once daily, with food)-based regimens were prospectively enrolled after signing a written informed consent.

Plasma and IC (intraperipheral blood mononuclear cell [intra-PBMC]) antiviral concentrations of ATV and RTV were measured at every visit using validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) methods (with direct evaluation of cell volume) (21, 22).

PBMC-associated and plasma ATV and RTV concentrations were measured by validated HPLC-MS and HPLC-photodiode array (HPLC-PDA) methods, respectively. Median values of individual measurements were considered and expressed as nanograms per milliliter.

Whole-blood samples were stored at −20°C for pharmacogenetic analysis. Genomic DNA was extracted using a QIAamp whole-blood minikit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. Genotyping was conducted by real time-based allelic discrimination with the use of standard methods (Applied Biosystems, Foster City, CA, USA). All primers, probes, and PCR conditions used are available on request. The single-nucleotide polymorphisms analyzed were PXR 63396 C→T (rs2472677, encoding PXR), ABCB1 3435 C→T (rs1045642, encoding P-glycoprotein), and SLCO1B1 521 T→C (rs4149056, encoding OATP1B1) and were grouped as dichotomous variables (according to available literature data).

For descriptive statistics, continuous variables were described as medians (25th to 75th percentiles [interquartile range {IQR}]) and categorical variables as frequencies (percentages). All polymorphisms were tested for Hardy-Weinberg equilibrium (http://www.oege.org/software/hwe-mr-calc.shtml). Mann-Whitney analysis was used to compare previously identified relevant genotypes (PXR 63396TT, ABCB1 3435CT/TT, and SLCO1B1 521TC/CC) with plasma and IC concentrations, as well as IC-to-plasma ratios (IPr) and changes over time. Linear regression analysis was used to investigate the potential influences of the three SNPs on plasma and IC concentrations changes over time. Statistical analyses were performed using the PASW software package version 23.0 (SPSS, Chicago, IL, USA), accepting statistical significance at two-sided P values of <0.05.

Twenty HIV-positive pregnant women were enrolled from November 2013 to January 2016. Baseline characteristics are reported in Table 1. The viroimmunological, clinical, and pharmacokinetic results have been reported elsewhere (23).

View this table:
  • View inline
  • View popup
TABLE 1

Patient characteristics

PXR 63396 CC, CT, and TT genotypes were observed in 6 (30%), 8 (40%), and 6 (30%) individuals, respectively; ABCB1 3435 CC, CT, and TT genotypes were observed in 12 (60%), 5 (25%), and 3 (15%) individuals, respectively; and SLCO1B1 521 TT, TC, and CC genotypes were observed in 16 (80%), 3 (15%), and 1 (5%) individuals, respectively. All SNPs were in Hardy-Weinberg equilibrium (P > 0.05). In PXR 63396 TT carriers, third-trimester ATV concentrations were lower in plasma (468 ng/ml [range, 262 to 746 ng/ml] versus 810 ng/ml [range, 341 to 1,338 ng/ml], respectively; P = 0.39) and higher intracellularly (1,224 ng/ml [range, 823 to 1,967 ng/ml] versus 640 ng/ml [range, 394 to 1,906 ng/ml], respectively; P = 0.11); IPr were significantly higher (2.6 [range, 1.6 to 3.5] versus 0.96 [range, 0.5 to 2]; P = 0.03, respectively).

Compared to postpartum, ATV plasma concentrations were not significantly lower (negative values indicate decreases and positive values indicate increases) in the third trimester (−315 ng/ml [−1,121 to +129 ng/ml]), with stable IPr (+0.12 ng/ml [−0.44 to +1.35 ng/ml]). PXR 63396 TT carriers, despite a greater decrease in plasma concentrations (−397 versus −247 ng/ml, respectively), showed an increase in IC levels (+95 versus −241 ng/ml, respectively) and in IPr (+0.42 versus +0.12, respectively). The association between ATV-RTV plasma concentrations, IC concentrations, and IPr according to the studied SNPs are shown in Fig. 1 and in Table S1 in the supplemental material.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Intracellular-to-plasma ratios of atazanavir (above) and ritonavir (below) according to single nucleotide polymorphisms in the studied genes. Boxes (ordered according to trimester of pregnancy) represent interquartile ranges, horizontal lines represent median values, and whiskers represent standard deviations; circles and stars represent outliers.

Logistic regression analysis (including all three genotypes) identifying predictors of third-trimester changes (versus postpartum concentrations) showed the SLCO1B1 521 TC/CC genotypes to be predictors of ATV changes (P = 0.059 for plasma and P = 0.051 for IC) and PXR 63396 TT genotypes to be predictors of RTV changes (IPr, P = 0.025) in the third trimester.

We observed minimal changes in ATV and RTV concentrations in HIV-positive pregnant patients; this variability could be explained by genetic variants (23).

For this purpose, we studied SNPs in genes encoding OATP1B1, P-gp, and PXR. PXR may influence the expression of P-gp as well as other membrane transporters, and it is activated by a huge variety of endobiotics and xenobiotics, including several drugs (24, 25). It has been demonstrated that PXR regulates the expression of CYP3A4/5 and P-gp-encoding genes and it has been associated with ATV plasma exposure (T allele at position 63396) (12, 13). We observed that a TT genotype in PXR 63396 was associated with higher ATV IPr and less variability in IC concentrations during the third trimester. Furthermore, multivariate logistic regression analysis identified single-nucleotide polymorphisms in OATP1B1-encoding genes as being relevant for ATV plasma concentration changes during the third trimester. Available data are limited but suggest that hepatic uptake (and therefore the amount of drug available for metabolism) may be mediated by OATP1B1 transport (8).

Possible limitations of this study are the limited sample size, the limited amount of drug measurement, and the lack of serum markers that could help in understanding the complex interplay between genetically determined and pregnancy-induced changes.

Further studies may clarify the role of different SNPs on antiretroviral transport during pregnancy, as well as the clinical impact of IC ATV and RTV accumulation according to different genotypes. These results may be relevant for allowing tailored treatment strategies during pregnancy.

FOOTNOTES

    • Received 22 February 2018.
    • Returned for modification 15 March 2018.
    • Accepted 21 April 2018.
    • Accepted manuscript posted online 14 May 2018.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.00309-18.

  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland.
  2. 2.↵
    1. Ford J,
    2. Khoo SH,
    3. Back DJ
    . 2004. The intracellular pharmacology of antiretro viral protease inhibitors. J Antimicrob Chemother 54:982–990. doi:10.1093/jac/dkh487.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bazzoli C,
    2. Jullien V,
    3. Le Tiec C,
    4. Rey E,
    5. Mentré F,
    6. Taburet AM
    . 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 49:17–45. doi:10.2165/11318110-000000000-00000.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Khoo SH,
    2. Hoggard PG,
    3. Williams I,
    4. Meaden ER,
    5. Newton P,
    6. Wilkins EG,
    7. Smith A,
    8. Tjia JF,
    9. Lloyd J,
    10. Jones K,
    11. Beeching N,
    12. Carey P,
    13. Peters B,
    14. Back DJ
    . 2002. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 46:3228–3235. doi:10.1128/AAC.46.10.3228-3235.2002.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Crommentuyn KM,
    2. Mulder JW,
    3. Mairuhu AT,
    4. van Gorp EC,
    5. Meenhorst PL,
    6. Huitema AD,
    7. Beijnen JH
    . 2004. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther 9:779–785.
    OpenUrlPubMedWeb of Science
  6. 6.↵
    1. Breilh D,
    2. Pellegrin I,
    3. Rouzés A,
    4. Berthoin K,
    5. Xuereb F,
    6. Budzinski H,
    7. Munck M,
    8. Fleury HJ,
    9. Saux MC,
    10. Pellegrin JL
    . 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305–1310. doi:10.1097/00002030-200406180-00009.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Ford J,
    2. Boffito M,
    3. Maitland D,
    4. Hill A,
    5. Back D,
    6. Khoo S,
    7. Nelson M,
    8. Moyle G,
    9. Gazzard B,
    10. Pozniak A
    . 2006. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother 58:1009–1016. doi:10.1093/jac/dkl379.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Hartkoorn RC,
    2. Kwan WS,
    3. Shallcross V,
    4. Chaikan A,
    5. Liptrott N,
    6. Egan D,
    7. Sora ES,
    8. James CE,
    9. Gibbons S,
    10. Bray PG,
    11. Back DJ,
    12. Khoo SH,
    13. Owen A
    . 2010. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20:112–120. doi:10.1097/FPC.0b013e328335b02d.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Huang L,
    2. Wring SA,
    3. Woolley JL,
    4. Brouwer KR,
    5. Serabjit-Singh C,
    6. Polli JW
    . 2001. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29:754–760.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Focà E,
    2. Ripamonti D,
    3. Motta D,
    4. Torti C
    . 2012. Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use. Drugs 72:1161–1173. doi:10.2165/11631070-000000000-00000.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. D'Avolio A,
    2. Carcieri C,
    3. Cusato J,
    4. Simiele M,
    5. Calcagno A,
    6. Allegra S,
    7. Sciandra M,
    8. Trentini L,
    9. Di Perri G,
    10. Bonora S
    . 2014. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother 69:3061–3066. doi:10.1093/jac/dku234.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Siccardi M,
    2. D'Avolio A,
    3. Baietto L,
    4. Gibbons S,
    5. Sciandra M,
    6. Colucci D,
    7. Bonora S,
    8. Khoo S,
    9. Back DJ,
    10. Di Perri G,
    11. Owen A
    . 2008. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 47:1222–1225. doi:10.1086/592304.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Schipani A,
    2. Siccardi M,
    3. D'Avolio A,
    4. Baietto L,
    5. Simiele M,
    6. Bonora S,
    7. Rodríguez Novoa S,
    8. Cuenca L,
    9. Soriano V,
    10. Chierakul N,
    11. Saguenwong N,
    12. Chuchuttaworn C,
    13. Hoskins JM,
    14. Dvorak AM,
    15. McLeod HL,
    16. Davies G,
    17. Khoo S,
    18. Back DJ,
    19. Di Perri G,
    20. Owen A
    . 2010. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 54:5242–5250. doi:10.1128/AAC.00781-10.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Eichelbaum M,
    2. Fromm MF,
    3. Schwab M
    . 2004. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26:180–185. doi:10.1097/00007691-200404000-00017.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Michaud V,
    2. Bar-Magen T,
    3. Turgeon J,
    4. Flockhart D,
    5. Desta Z,
    6. Wainberg MA
    . 2012. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64:803–833. doi:10.1124/pr.111.005553.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Tirona RG,
    2. Leake BF,
    3. Merino G,
    4. Kim RB
    . 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675. doi:10.1074/jbc.M103792200.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Kohlrausch FB,
    2. de Cássia Estrela R,
    3. Barroso PF,
    4. Suarez-Kurtz G
    . 2010. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 69:95–98. doi:10.1111/j.1365-2125.2009.03551.x.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Iwai M,
    2. Suzuki H,
    3. Ieiri I,
    4. Otsubo K,
    5. Sugiyama Y
    . 2004. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749–757. doi:10.1097/00008571-200411000-00006.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. van der Deure WM,
    2. Friesema EC,
    3. de Jong FJ,
    4. de Rijke YB,
    5. de Jong FH,
    6. Uitterlinden AG,
    7. Breteler MM,
    8. Peeters RP,
    9. Visser TJ
    . 2008. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 149:4695–4701. doi:10.1210/en.2008-0169.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Mittal A,
    2. Pachter L,
    3. Nelson JL,
    4. Kjærgaard H,
    5. Smed MK,
    6. Gildengorin VL,
    7. Zoffmann V,
    8. Hetland ML,
    9. Jewell NP,
    10. Olsen J,
    11. Jawaheer D
    . 2015. Pregnancy-induced changes in systemic gene expression among healthy women and women with rheumatoid arthritis. PLoS One 10:e0145204. doi:10.1371/journal.pone.0145204.
    OpenUrlCrossRef
  21. 21.↵
    1. Simiele M,
    2. D'Avolio A,
    3. Baietto L,
    4. Siccardi M,
    5. Sciandra M,
    6. Agati S,
    7. Cusato J,
    8. Bonora S,
    9. Di Perri G
    . 2011. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter counter to determine intracellular drug concentrations. Antimicrob Agents Chemother 55:2976–2978. doi:10.1128/AAC.01236-10.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Colombo S,
    2. Buclin T,
    3. Cavassini M,
    4. Décosterd LA,
    5. Telenti A,
    6. Biollaz J,
    7. Csajka C
    . 2006. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 50:3801–3808. doi:10.1128/AAC.00098-06.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Focà E,
    2. Calcagno A,
    3. Bonito A,
    4. Simiele M,
    5. Domenighini E,
    6. D'Avolio A,
    7. Quiros Roldan E,
    8. Trentini L,
    9. Casari S,
    10. Di Perri G,
    11. Castelli F,
    12. Bonora S
    . 2017. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. J Antimicrob Chemother 72:3163–3166. doi:10.1093/jac/dkx274.
    OpenUrlCrossRef
  24. 24.↵
    1. Chang TK,
    2. Waxman DJ
    . 2006. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51–73. doi:10.1080/03602530600569828.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Chen S,
    2. Yueh MF,
    3. Evans RM,
    4. Tukey RH
    . 2012. Pregnane-X-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice. Hepatology 56:658–667. doi:10.1002/hep.25671.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Pavek P
    . 2016. Pregnane X receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions. Front Pharmacol 7:456. doi:10.3389/fphar.2016.00456.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir
Emanuele Focà, Andrea Calcagno, Andrea Bonito, Jessica Cusato, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Filippo Castelnuovo, Giovanni Di Perri, Francesco Castelli, Stefano Bonora
Antimicrobial Agents and Chemotherapy Jun 2018, 62 (7) e00309-18; DOI: 10.1128/AAC.00309-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir
Emanuele Focà, Andrea Calcagno, Andrea Bonito, Jessica Cusato, Elisabetta Domenighini, Antonio D'Avolio, Eugenia Quiros Roldan, Laura Trentini, Filippo Castelnuovo, Giovanni Di Perri, Francesco Castelli, Stefano Bonora
Antimicrobial Agents and Chemotherapy Jun 2018, 62 (7) e00309-18; DOI: 10.1128/AAC.00309-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

HIV
antiretroviral agents
antiviral pharmacology

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596